TBK1: A key regulator and potential treatment target for interferon positive Sj ögren's syndrome, systemic lupus erythematosus and systemic sclerosis.

CONCLUSIONS: TBK1 inhibition reduced expression of ISGs in PBMCs from IFNpos patients with systemic autoimmune diseases indicating TBK1 as a potential treatment target. PMID: 29673738 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/29673738?dopt=Abstract

Source: Journal of Autoimmunity - April 16, 2018 Category: Allergy & Immunology Authors: Bodewes ILA, Huijser E, van Helden-Meeuwsen CG, Tas L, Huizinga R, Dalm VASH, van Hagen PM, Groot N, Kamphuis S, van Daele PLA, Versnel MA Tags: J Autoimmun Source Type: research